VivoSim Labs Expands Human-Based Toxicology Services to Asia-Pacific Through Strategic Distribution Partnerships
Key Insights
VivoSim Labs (search) has appointed JCBio (search) as distributor in Korea and Tekon Biotech (search) as distributor in China for its NAMKind (search)™ human-based toxicology services targeting liver (search) and small intestine (search) screening.
The expansion addresses growing demand for human-relevant toxicology testing, with China's in-vitro toxicology market projected to grow from $1.05 billion in 2023 to $2.26 billion by 2030.
NAMKind (search)™ platform offers 30-day turnaround times and aims to detect toxicities often missed by animal models, particularly relevant for complex modalities like ADCs and Traditional Chinese Medicine (search) compounds.
VivoSim Labs (search) has significantly expanded its commercial footprint in Asia-Pacific by signing distribution agreements with JCBio (search) in Korea and Tekon Biotech (search) in China for its NAMKind (search)™ human-based toxicology services. The partnerships provide regional pharmaceutical and biotechnology companies with faster access to liver (search) and small intestine (search) toxicology screening using three-dimensional human tissue models.
Growing Market Demand for Human-Relevant Toxicology
The expansion comes as global demand for New Approach Methodologies (NAMs) accelerates across the pharmaceutical industry. Drug developers are increasingly seeking earlier readouts, clearer translation to clinical outcomes, and meaningful reductions in late-stage attrition. VivoSim's NAMKind (search)™ services address this need with a streamlined "molecules in, data out" model that supports small molecules, biologics, and advanced modalities with a targeted 30-day turnaround time per compound.
China represents a particularly significant opportunity, with the country's in-vitro toxicology testing market projected to grow from approximately $1.05 billion in 2023 to $2.26 billion by 2030, driven by increasing R&D investment and evolving regulatory standards.
Addressing Regional Toxicology Challenges
Sanger Chang, President of Tekon Biotech (search), emphasized the strategic importance of this technology for China's evolving pharmaceutical landscape. "The pharmaceutical industry in China is currently undergoing a massive transformation, pivoting aggressively from generic manufacturing to 'First-in-Class' source innovation," Chang said. "However, this shift brings higher stakes. Our clients are increasingly concerned about late-stage clinical failures, particularly regarding liver (search) safety."
The need for better predictive tools is particularly acute in China, where Drug-Induced Liver Injury (search) (DILI) incidence is estimated at 23.80 per 100,000 people—significantly higher than in Western populations. Chang noted that traditional animal models have historically struggled to predict toxicity for complex modalities like Antibody-Drug Conjugates (search) (ADCs) or specific compounds found in Traditional Chinese Medicine (search) (TCM), which are unique pillars of the local market.
Regulatory Alignment and Technology Advantages
The distribution agreements align with broader regulatory momentum toward NAM adoption. Korea's Ministry of Food and Drug Safety (search) (MFDS) has been moving in step with international initiatives, including the U.S. FDA (search), toward evaluation and acceptance of scientifically robust NAM-based evidence where it improves decision-making. This alignment aims to accelerate adoption of new techniques that emphasize performance, predictivity, and relevance to human outcomes, especially in high-impact organs like liver (search) and gastrointestinal tissues (search).
VivoSim anticipates accelerated adoption of human tissue models following the U.S. FDA (search) announcement on April 10, 2025 to refine animal testing requirements in favor of non-animal NAM methods.
Commercial Strategy and Implementation
Tony Lialin, Chief Commercial Officer at VivoSim, highlighted the practical advantages of the NAMKind (search)™ platform. "Global demand for human-relevant toxicology is shooting up, and the industry needs solutions that deliver real-world impact right now," Lialin said. "NAMKind™ makes it practical—small or large molecules in, decision-ready data out—with a targeted 30-day turnaround time per study."
The platform is engineered for efficient program execution and faster "go/no-go" decisions. By delivering human-based screening insights earlier, particularly around liver (search) and GI liabilities, customers may avoid costly downstream failures, reduce rework, and prioritize assets with greater confidence.
In Korea, JCBio (search) will support regional customers by providing local coordination and scientific engagement to streamline evaluations, from project scoping and sample logistics to data review and program iteration.
Market Impact and Future Outlook
NAMKind (search)™ services are designed to save time, reduce risk, and cut costs at scale. The platform has the potential to save customers millions by identifying risk earlier and focusing investment where it has the highest probability of success. Chang emphasized that the NAMKind™ platform offers "Final Pass Pre-IND" assurance that clients need, helping Chinese innovators de-risk their pipelines early and ensuring that only the safest, most promising candidates advance to clinical trials.
With the distribution agreements now in place, NAMKind (search)™ liver (search) and small intestine (search) toxicology services are available via local distributor engagement across Korea and China. VivoSim continues to scale capacity to support expanding global demand and urgent development needs in the rapidly evolving pharmaceutical landscape.